Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$8.23 USD
+0.60 (7.86%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Vir Biotechnology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -615.12 | 515.84 | 528.58 | -298.67 | -174.68 |
Depreciation/Amortization & Depletion | 10.75 | -2.16 | 5.57 | 7.82 | 4.34 |
Net Change from Assets/Liabilities | -304.59 | 665.37 | -628.39 | 29.52 | 8.20 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 130.18 | 484.21 | 46.65 | 70.38 | 32.51 |
Net Cash From Operating Activities | -778.79 | 1,663.25 | -47.59 | -190.94 | -129.63 |
Property & Equipment | -21.57 | -68.01 | -21.82 | -6.37 | -8.94 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 186.20 | -1,125.46 | -119.00 | -3.49 | -247.22 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 164.63 | -1,193.46 | -140.81 | -9.86 | -256.16 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 7.77 | 36.22 | 100.59 | 533.97 | 444.88 |
Issuance (Repayment) of Debt | -0.29 | -0.26 | -0.26 | -0.25 | 4.37 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -1.20 | 0.00 | -4.25 | 0.00 |
Net Cash from Financing Activities | 7.48 | 34.76 | 100.33 | 529.47 | 449.24 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -606.68 | 504.55 | -88.07 | 328.67 | 63.45 |
Cash at Beginning of Period | 867.97 | 363.42 | 451.49 | 122.82 | 59.36 |
Cash at End of Period | 261.29 | 867.97 | 363.42 | 451.49 | 122.82 |
Diluted Net EPS | -4.59 | 3.83 | 3.96 | -2.51 | -5.76 |
Fiscal Year End for Vir Biotechnology, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -615.12 | -499.14 | -335.73 | -140.96 |
Depreciation/Amortization & Depletion | NA | 10.75 | 4.92 | -1.98 | -3.73 |
Net Change from Assets/Liabilities | NA | -304.59 | -271.84 | -242.15 | 10.73 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 130.18 | 95.21 | 64.83 | 8.18 |
Net Cash From Operating Activities | NA | -778.79 | -670.86 | -515.03 | -125.78 |
Property & Equipment | NA | -21.57 | -20.04 | -16.32 | -6.87 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 186.20 | 289.48 | 344.72 | 104.95 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 164.63 | 269.44 | 328.39 | 98.08 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 7.77 | 6.00 | 5.66 | 2.41 |
Issuance (Repayment) of Debt | NA | -0.29 | -0.20 | -0.13 | -0.07 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 7.48 | 5.80 | 5.52 | 2.34 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -606.68 | -395.62 | -181.11 | -25.36 |
Cash at Beginning of Period | NA | 867.97 | 867.97 | 867.97 | 867.97 |
Cash at End of Period | NA | 261.29 | 472.35 | 686.86 | 842.61 |
Diluted Net EPS | NA | -0.86 | -1.22 | -1.45 | -1.06 |